A Double Blind, Placebo Controlled, Single and Repeat Dose Escalation Study of GSK2838232 With and Without Ritonavir for 8-11 Days in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs GSK 2838232 (Primary) ; Ritonavir
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 05 May 2017 Status changed from completed to discontinued.
- 30 Jul 2015 Status changed from suspended to completed, as reported by ClinicalTrials.gov.
- 05 Jun 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.